Vermont New Drug Template B. BRAUN MEDICAL INC.
CONTIDENTIAL AND PROPRIETARY
ATTORNEY-CLIENT FRIVILEGED

								Breakthrough				
					WAC (as of date	Date of		therapy	Priority	Date and price of acquisition if the		
					of commercial	Commercial	Estimated volume of patients	designation?	Review	drug was not developed by the	A description of the marketing and pricing	
Manufacturer Name	NDC	Name of Prescription Drug	Strength	Pack Size/Volume	availability)	Availability	who may be prescribed drug	(Y/N)	? (Y/N)	manufacturer else N/A	plans used in the launch of the new drug	General Comments
												There was a question regarding the course of therapy for this product that required additional research. Due to the foregoing, we were unable to immediately calculate whether the WAC price, based on the course of therapy, exceeded the threshold to trigger the new drug notice and reporting, which thereby resulted in a delay of a few days in providing the required notice.
											WAC pricing is based on B. Braun's assessment of costs to develop and produce the drug as well as an assessment of market pricing for similar products.	prompt pay or other discounts, rebates, chargebacks, or other reductions in price. By providing a distributor in-to-stop, chirc, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of
B. Braun Medical Inc	00264-4400-54	Magnesium Sulfate in 5% Dextrose Injection	1g/100 mL	. 100 mL	\$6.38	9/9/2021	400,000	N	N	n/a		coverage or reimbursement for any referenced product. These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or S. Braun's Yew of the actual prices at which B. Braun's products may be resold by wholesalers or other customers.